Risk-Adjusted Performance and Market Timing of ESG Mutual Funds in India: A Multifactor Analysis
Journal of Asia Entrepreneurship and Sustainability · 07.11.2026
DOI: 10.66635/mmkmm477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asia Entrepreneurship and Sustainability, online erschienen am 07.11.2026. Verfasst von Thasneem J und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This study examines the risk adjusted performances and market timing abilities of 7 ESG Mutual Funds in India using daily data from 2021-2025. This study uses Capital Asset Pricing Model (CAPM), Carhart four factor model and Treynor-Mazuy Market Timing Model to find out the performances of the ESG Mutual Funds. The NIFTY 100 ESG and NIFTY 500 have been taken as benchmark to examine the performance of the Mutual Funds. Newey-West HAC standard errors are used to make inference robust to heteroskedasticity and autocorrelation. It has been found that the risk adjusted performances differ between different Mutual Funds. Quant ESG Mutual Fund has shown positive and significant alphas under CAPM model. However, it depends on the benchmark under Carhart model. Evidence of market timing is limited and inconsistent: Kotak and Quant show significantly negative Gamma under the ESG benchmark, while SBI shows significantly positive Gamma under the NIFTY 500 only.
Zitieren
APA
J, T., & Lawrence, D. A. (2026). Risk-Adjusted Performance and Market Timing of ESG Mutual Funds in India: A Multifactor Analysis. Journal of Asia Entrepreneurship and Sustainability. https://doi.org/10.66635/mmkmm477
Vancouver
J T, Lawrence DA. Risk-Adjusted Performance and Market Timing of ESG Mutual Funds in India: A Multifactor Analysis. Journal of Asia Entrepreneurship and Sustainability. 2026. doi:10.66635/mmkmm477
BibTeX
@article{J2026,
author = {J, Thasneem and Lawrence, Dr. Arun},
title = {Risk-Adjusted Performance and Market Timing of ESG Mutual Funds in India: A Multifactor Analysis},
journal = {Journal of Asia Entrepreneurship and Sustainability},
year = {2026},
doi = {10.66635/mmkmm477}
}
EUVIMED